Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer
Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend.
Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend.
Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.